263 related articles for article (PubMed ID: 36411032)
21. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
22. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
23. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
[TBL] [Abstract][Full Text] [Related]
24. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
25. Genetic characterization of early onset ovarian carcinoma.
Bernards SS; Norquist BM; Harrell MI; Agnew KJ; Lee MK; Walsh T; Swisher EM
Gynecol Oncol; 2016 Feb; 140(2):221-5. PubMed ID: 26718727
[TBL] [Abstract][Full Text] [Related]
26. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
[TBL] [Abstract][Full Text] [Related]
27. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families.
Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D
Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077
[TBL] [Abstract][Full Text] [Related]
28. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.
Yang X; Song H; Leslie G; Engel C; Hahnen E; Auber B; Horváth J; Kast K; Niederacher D; Turnbull C; Houlston R; Hanson H; Loveday C; Dolinsky JS; LaDuca H; Ramus SJ; Menon U; Rosenthal AN; Jacobs I; Gayther SA; Dicks E; Nevanlinna H; Aittomäki K; Pelttari LM; Ehrencrona H; Borg Å; Kvist A; Rivera B; Hansen TVO; Djursby M; Lee A; Dennis J; Bowtell DD; Traficante N; Diez O; Balmaña J; Gruber SB; Chenevix-Trench G; Investigators K; Jensen A; Kjær SK; Høgdall E; Castéra L; Garber J; Janavicius R; Osorio A; Golmard L; Vega A; Couch FJ; Robson M; Gronwald J; Domchek SM; Culver JO; de la Hoya M; Easton DF; Foulkes WD; Tischkowitz M; Meindl A; Schmutzler RK; Pharoah PDP; Antoniou AC
J Natl Cancer Inst; 2020 Dec; 112(12):1242-1250. PubMed ID: 32107557
[TBL] [Abstract][Full Text] [Related]
29. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P
Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731
[TBL] [Abstract][Full Text] [Related]
30. Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer.
Soukupová J; Lhotová K; Janatová M; Kleiblová P; Vočka M; Foretová L; Zikán M; Kleibl Z
Klin Onkol; 2021; 34(1):26-32. PubMed ID: 33657816
[TBL] [Abstract][Full Text] [Related]
31. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
[TBL] [Abstract][Full Text] [Related]
32. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract][Full Text] [Related]
33. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Song H; Dicks E; Ramus SJ; Tyrer JP; Intermaggio MP; Hayward J; Edlund CK; Conti D; Harrington P; Fraser L; Philpott S; Anderson C; Rosenthal A; Gentry-Maharaj A; Bowtell DD; Alsop K; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Høgdall E; Høgdall CK; Jensen A; Kjaer SK; Lubiński J; Huzarski T; Jakubowska A; Gronwald J; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Odunsi K; Goode EL; Menon U; Jacobs IJ; Gayther SA; Pharoah PD
J Clin Oncol; 2015 Sep; 33(26):2901-7. PubMed ID: 26261251
[TBL] [Abstract][Full Text] [Related]
34. Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition?
Horackova K; Janatova M; Kleiblova P; Kleibl Z; Soukupova J
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069345
[TBL] [Abstract][Full Text] [Related]
35. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
[TBL] [Abstract][Full Text] [Related]
36. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
37. A decade of RAD51C and RAD51D germline variants in cancer.
Boni J; Idani A; Roca C; Feliubadaló L; Tomiak E; Weber E; Foulkes WD; Orthwein A; El Haffaf Z; Lazaro C; Rivera B
Hum Mutat; 2022 Mar; 43(3):285-298. PubMed ID: 34923718
[TBL] [Abstract][Full Text] [Related]
38. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.
Lilyquist J; LaDuca H; Polley E; Davis BT; Shimelis H; Hu C; Hart SN; Dolinsky JS; Couch FJ; Goldgar DE
Gynecol Oncol; 2017 Nov; 147(2):375-380. PubMed ID: 28888541
[TBL] [Abstract][Full Text] [Related]
39. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on
Lee A; Mavaddat N; Cunningham A; Carver T; Ficorella L; Archer S; Walter FM; Tischkowitz M; Roberts J; Usher-Smith J; Simard J; Schmidt MK; Devilee P; Zadnik V; Jürgens H; Mouret-Fourme E; De Pauw A; Rookus M; Mooij TM; Pharoah PP; Easton DF; Antoniou AC
J Med Genet; 2022 Dec; 59(12):1206-1218. PubMed ID: 36162851
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
